









市場行情
/
股票
/
nasdaq-celu
/

Celularity Inc

CELU

1.450USD

+0.200+16.00%

收盤 12/19, 16:00（美東）報價延遲15分鐘

40.91M總市值

虧損本益比TTM



Celularity Inc

1.450

+0.200+16.00%

概覽公司財務分析

概覽

公司

財務

分析

關於 Celularity Inc 公司

Celularity Inc. is a regenerative and cellular medicine company. The Company is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. It develops, manufactures and commercializes advanced biomaterial products derived from structural tissue components of the postpartum placental tissues, including the umbilical cord. Its advanced biomaterials include Celularity Tendon Wrap, FUSE Bone Void Filler and Celularity Placental Matrix. Its advanced biomaterial products include Biovance, Biovance 3L, CentaFlex, Interfyl and Rebound products.

Celularity Inc簡介



公司代碼CELU

公司名稱Celularity Inc

上市日期May 23, 2019

CEOHariri (Robert J)

員工數量123

證券類型Ordinary Share

年結日May 23

公司地址170 Park Ave

城市FLORHAM PARK

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編07932

電話19087682170

網址https://celularity.com/

公司代碼CELU

上市日期May 23, 2019

CEOHariri (Robert J)

Celularity Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. Robert J. (Bob) Hariri, M.D., Ph.D.

Chairman of the Board, Chief Executive Officer

2.86M

+0.11%

Mr. Vincent Levien

Independent Director

3.70K

Mr. Stephen A. Brigido

President - Degenerative Disease

Ms. Diane L. Parks

Independent Director

Dr. Peter H. Diamandis, M.D.

Independent Director

Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.

Independent Director

Mr. John R. Haines

Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary

Mr. Joseph Dossantos

Interim Chief Financial Officer

Mr. Carlos Ramirez

Senior Vice President - Investor Relations

名稱

名稱/職務

職務

持股

持股變動

Dr. Robert J. (Bob) Hariri, M.D., Ph.D.

Chairman of the Board, Chief Executive Officer

2.86M

+0.11%

Mr. Vincent Levien

Independent Director

3.70K

Mr. Stephen A. Brigido

President - Degenerative Disease

Ms. Diane L. Parks

Independent Director

Dr. Peter H. Diamandis, M.D.

Independent Director

Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.

Independent Director

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 11月20日週四

持股股東

股東類型

持股股東

佔比

Genting Bhd

22.36%

Hariri (Robert J)

10.09%

Starr International Company, Inc.

5.39%

Lincoln Alternative Strategies LLC

4.34%

C.V. Starr & Co., Inc.

2.70%

其他

55.11%

持股股東

佔比

Genting Bhd

22.36%

Hariri (Robert J)

10.09%

Starr International Company, Inc.

5.39%

Lincoln Alternative Strategies LLC

4.34%

C.V. Starr & Co., Inc.

2.70%

其他

55.11%

股東類型

持股股東

佔比

Corporation

26.71%

Individual Investor

12.96%

Investment Advisor

8.87%

Insurance Company

2.70%

Investment Advisor/Hedge Fund

1.32%

Hedge Fund

0.39%

Research Firm

0.19%

Family Office

0.04%

其他

46.82%

機構持股



更新時間: 12月8日週一

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

3.82M

13.73%

2025Q3

3.82M

16.36%

+119.97K

2025Q2

3.70M

17.46%

+189.07K

2025Q1

120

3.51M

18.18%

-579.52K

2024Q4

135

3.39M

17.70%

+120.20K

2024Q3

149

3.27M

18.60%

+20.75K

2024Q2

160

3.32M

18.56%

+109.90K

2024Q1

166

3.20M

18.29%

-780.71K

2023Q4

164

3.20M

20.76%

-511.70K

2023Q3

164

3.71M

20.21%

+96.25K

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Genting Bhd

6.34M

23.74%

Jul 24, 2025

Hariri (Robert J)

2.85M

10.7%

+3.28K

+0.12%

May 15, 2025

Starr International Company, Inc.

1.53M

5.73%

May 15, 2025

Lincoln Alternative Strategies LLC

1.23M

4.61%

+1.23M

Jul 14, 2025

C.V. Starr & Co., Inc.

764.07K

2.86%

Jun 30, 2025

The Vanguard Group, Inc.

500.13K

1.87%

Jun 30, 2025

Diamandis (Peter)

134.31K

0.5%

-63.82K

-32.21%

May 15, 2025

Parks (Diane L.)

23.61K

0.09%

-67.42K

-74.06%

May 15, 2025

Geode Capital Management, L.L.C.

134.82K

0.51%

-1.22K

-0.89%

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

iShares Micro-Cap ETF

DFA Dimensional US Sustainability Core 1 ETF

iShares Micro-Cap ETF

佔比0%

DFA Dimensional US Sustainability Core 1 ETF

佔比0%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

Feb 23, 2024

Merger

10→1

Feb 23, 2024

Merger

10→1

Feb 23, 2024

Merger

10→1

Feb 23, 2024

Merger

10→1

公告日期

類型

比率

Feb 23, 2024

Merger

10→1

Feb 23, 2024

Merger

10→1

Feb 23, 2024

Merger

10→1

Feb 23, 2024

Merger

10→1

常見問題

Celularity Inc的前五大股東是誰？



Celularity Inc的前五大股東如下：
Genting Bhd
持有股份：6.34M
佔總股份比例：23.74%。
Hariri (Robert J)
持有股份：2.85M
佔總股份比例：10.70%。
Starr International Company, Inc.
持有股份：1.53M
佔總股份比例：5.73%。
Lincoln Alternative Strategies LLC
持有股份：1.23M
佔總股份比例：4.61%。
C.V. Starr & Co., Inc.
持有股份：764.07K
佔總股份比例：2.86%。